EXKIVITY (mobocertinib) capsules
EXKIVITY is used to treat adult patients with a kind of lung cancer called non-small cell lung cancer (NSCLC). Brand Name: EXKIVITY (mobocertinib) capsules, for oral use Initial U.S. Approval: 2021
Home | Mobocertinib capsules
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient inquires under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
EXKIVITY (mobocertinib) capsules
Mobocertinib succinate is approved to treat: Non-small cell lung cancer (NSCLC). Mobocertinib succinate is also being studied in the treatment of other conditions.
A drug used to treat adults with non-small cell lung cancer that has spread and has certain mutations (changes) in the EGFR gene. It is used in patients whose cancer got worse during or after platinum chemotherapy. It is also being studied in the treatment of other conditions. Exkivity blocks certain proteins made by the mutated EGFR gene, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called mobocertinib succinate.
Mobocertinib is indicated for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Drug (Brand / Generic): EXKIVITY / mobocertinib
Current Indications: Non-small cell lung cancer (NSCLC)
Marketed by:: Takeda Pharmaceuticals America, Inc
Approval Date: 2021
Dosage forms and strengths of EXKIVITY (mobocertinib).
Capsules: 40 mg
Find Reference Updates
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer
Gonzalvez F, et al., Cancer discovery, Jul 2021
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ EXKIVITY (mobocertinib) capsules ”. Confirmation of the order for EXKIVITY (mobocertinib) capsules will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – EXKIVITY
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha